Form 4: Supernus Pharmaceuticals Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Padmanabh P. Bhatt, Sr. VP of IP, CSO at Supernus Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 21, 2024, Padmanabh P. Bhatt, Sr. VP of IP, CSO at Supernus Pharmaceuticals, exercised employee stock options to acquire 14,491 shares of common stock at a price of $25.30 per share.
• Simultaneously, Bhatt sold 14,491 shares of common stock at a weighted average price of $35.31, with individual sales ranging from $35.30 to $35.43.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on September 7, 2023.
• Following these transactions, Bhatt directly owns 8,570 shares of Supernus Pharmaceuticals common stock and 12,745 employee stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports routine stock transactions under a pre-existing plan.

Industry Context

Executive stock transactions are common and closely monitored, especially in pharmaceutical companies. The use of 10b5-1 plans allows insiders to sell shares without concerns about insider trading, as the plans are pre-arranged.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are part of a pre-planned trading strategy.

Key Dates